President Donald Trump’s deal to cut prices for popular weight-loss drugs like Wegovy and Zepbound will allow millions more ...
Preliminary research suggests that NG101, a drug from Neurogastrx, may lower the risk of nausea and vomiting in people taking ...
Mediaite on MSNOpinion
Credit Where It’s Due: Trump’s Weight-Loss Subsidy Is a Public-Health Game Changer
By subsidizing Wegovy and Zepbound, Trump may deliver one of the most consequential public-health interventions in decades.
Phase 2 data show significant reductions in nausea and vomiting that can cause patients to discontinue GLP-1s.
Investor's Business Daily on MSN
The Weight-Loss Drugs Craze Is Going Strong. But Stock Investors Should Know A Few Things.
Makers of weight-loss drugs saw their stocks surge in 2024, but no more. Now Trump's price deal adds new questions. Is the ...
A Trump administration deal to cut prices for popular weight-loss drugs like Wegovy and Zepbound will allow millions more ...
Certain GLP-1 weight loss medications will be available for as little as $149 per month, a sharp drop from the current ...
A Trump administration deal to cut prices for popular weight-loss drugs like Wegovy and Zepbound will allow millions more ...
Eli Lilly and Company (NYSE: LLY) today announced an agreement with the U.S. government to expand access to its obesity medicines and re ...
President Donald Trump has unveiled a deal with drugmakers Eli Lilly and Novo Nordisk to expand coverage and reduce prices ...
The nausea and other gastrointestinal side effects of weight loss drugs like Novo Nordisk’s Wegovy or Eli Lilly’s Zepbound will limit how much these drugs can help patients and stunt the overall ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback